The FDA has approved an adjuvant combination of pembrolizumab and belzutifan for high-risk clear cell renal cell carcinoma after surgery, positioning the regimen as a new postoperative option for eligible adults. The approval covers patients with clear cell RCC who have undergone resection of all or part of the kidney, reflecting continued expansion of immune checkpoint and hypoxia-pathway targeting. Pembrolizumab (an anti–PD-1 checkpoint inhibitor) plus belzutifan (a HIF-2α inhibitor) combines immune activation with suppression of a tumor oxygen-sensing axis. The decision adds a clinically differentiated option to the adjuvant landscape, where benefits depend heavily on patient risk profiles and tolerability. Clinicians and developers will now focus on uptake considerations—particularly sequencing and adverse-event management—while competitors recalibrate adjuvant trial strategies against checkpoint-based regimens.